Everett Harris & Co. CA Sells 7,039 Shares of Edwards Lifesciences Co. (NYSE:EW)

Everett Harris & Co. CA lessened its position in Edwards Lifesciences Co. (NYSE:EW) by 7.2% during the third quarter, Holdings Channel reports. The fund owned 90,894 shares of the medical research company’s stock after selling 7,039 shares during the period. Everett Harris & Co. CA’s holdings in Edwards Lifesciences were worth $5,998,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. increased its stake in Edwards Lifesciences by 59.4% in the third quarter. Blue Trust Inc. now owns 8,049 shares of the medical research company’s stock valued at $531,000 after acquiring an additional 2,998 shares during the last quarter. Net Worth Advisory Group bought a new position in Edwards Lifesciences in the third quarter valued at $437,000. Aaron Wealth Advisors LLC bought a new position in Edwards Lifesciences in the third quarter valued at $273,000. V Square Quantitative Management LLC grew its stake in shares of Edwards Lifesciences by 10.6% during the third quarter. V Square Quantitative Management LLC now owns 15,026 shares of the medical research company’s stock valued at $992,000 after buying an additional 1,437 shares during the last quarter. Finally, Trust Co. of Vermont grew its stake in shares of Edwards Lifesciences by 36.1% during the third quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock valued at $199,000 after buying an additional 801 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,250 shares of company stock worth $1,099,238. Company insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $100.00 to $70.00 in a research note on Thursday, July 25th. Piper Sandler reduced their price objective on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a research note on Thursday, July 25th. Stifel Nicolaus reduced their price objective on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, July 25th. Finally, Truist Financial dropped their target price on shares of Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating for the company in a report on Friday, September 13th. Fifteen equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $75.81.

Edwards Lifesciences Stock Up 2.6 %

EW traded up $1.80 during trading on Friday, hitting $70.27. The stock had a trading volume of 5,424,803 shares, compared to its average volume of 4,573,039. The company has a market capitalization of $42.34 billion, a PE ratio of 30.29, a PEG ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The stock has a 50 day simple moving average of $67.81 and a two-hundred day simple moving average of $79.28.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the previous year, the firm posted $0.66 earnings per share. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, research analysts predict that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.